Examples of amyloid-negative (left) and amyloid-positive (right) positron emission tomography (PET) scans. In this figure, the amyloid-PET ligand [18F]AZD4694 is shown. The hotter colours indicate more amyloid-PET tracer binding, and colder colours indicate low amyloid-PET tracer binding. The prototypical amyloid-positive PET pattern is of elevated amyloid in the brain’s posterior cingulate cortex, prefrontal cortex, as well as lateral parietal and temporal cortices. These regions display minimal tracer uptake in the amyloid-negative case (left), who has low binding across the whole cerebral cortex. Finally, it is important to note that amyloid-PET tracers have some binding to white matter, which explains the small amounts of hotter colours in the amyloid-negative case.

More information on amyloid-PET visual reads can be found in Johnson KA, Minoshima S, Bohnen NI, et al. “Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer’s Association”. Alzheimers Dement. 2013;54(3):476-490

file_download Download in HQ

Related content

image Image The physical and social exposome in brain health and dementia across the lifespan
The physical and social exposome in brain health and dementia across the lifespan

Social and physical exposome factors—like poverty, pollution, and inequality—accumulate over time, shaping biological aging and cognitive decline. Through inflammation and cellular stress, these exposures drive neurodegeneration, highlighting the need for longitudinal, integrative research.

12.11.2025 Alzheimer’s Disease
description Article
The Physical and Social Exposome in Brain Health and Dementia

The exposome reframes dementia as the product of cumulative physical and social exposures-like pollution, nutrition, and inequality-across life. These factors shape brain aging through inflammation and epigenetic change. Lifespan, global studies are key to equitable dementia prevention.

12.11.2025 Alzheimer’s Disease
image Image A multi-arm, multi-stage platform trial illustration
A multi-arm, multi-stage platform trial illustration
29.04.2025 Alzheimer’s Disease